← All diseases
Brain and nervous system
Primary lateral sclerosis
Would you like to receive notifications when new research on Primary Lateral Sclerosis becomes available? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, above every publication you'll see one sentence explaining what was studied — and you'll get notified as soon as new research on Primary lateral sclerosis is published. View what Premium costs.
Publications and studies (2508)
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Clinically discordant siblings with spinal muscular atrophy: insights from their patient-specific iPSC-derived motor neurons and literature review. (2026/02/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Effectiveness and Safety of Nusinersen Among Adults with 5q-Spinal Muscular Atrophy: A Multicenter Disease Registry in China. (2026/02/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Phenotypic continuum in IGHMBP2-related disorders: a portfolio of cases from typical to Guillain-Barré syndrome-like presentation. (2026/02/01) ♡
- Spinal circuit mechanisms constrain therapeutic windows for ALS intervention: A computational modeling study. (2026/02/01) ♡
- Learnings from a registry-based cohort study for spinal muscular atrophy disease. (2026/02/01) ♡
- Insights into the human pharmacokinetics and metabolism of branaplam, a splicing modulator of a survival motor neuron-2 and huntingtin pre-mRNAs, in infants and adults. (2026/02/01) ♡
- OTUD6A drives dopaminergic neuronal degeneration of Parkinson's disease through deubiquitinating ACTG1 in neuronal cells. (2026/02/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Targeting lipid metabolism in neurodegenerative diseases: From experimental to clinical. (2026/02/01) ♡
- You look at life through a different lens: a phenomenological study of living with amyotrophic lateral sclerosis. (2026/02/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Neuroprotective mechanisms of sodium butyrate in Parkinson's disease in preclinical rodent models: a systematic review and meta-analysis. (2026/02/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Contaminating plasmid sequences and disrupted vector genomes in the liver following adeno-associated virus gene therapy. (2026/02/01) ♡
- A gut-activated NHR-86-CYP pathway mediates the neuroprotective effects of Enterococcus faecium probiotics in a nematode model of amyotrophic lateral sclerosis. (2026/01/30) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Targeting gut-brain-immune axis in amyotrophic lateral sclerosis. (2026/01/29) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case Report: Spinal muscular atrophy with IgA nephropathy: a coincidence or association? (2026/01/22) ♡
- Age-period-cohort effect on motor neuron disease mortality in the United States, 2001-2020. (2026/01/21) ♡
- From policy to practice: premarital spinal muscular atrophy screening as a public health initiative in northern Türkiye. (2026/01/21) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Alteration of hippocampal parvalbumin interneurons underlies memory impairment in rat model of Parkinson's disease. (2026/01/20) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Clinical safety of ultra-high-dose methylcobalamin in patients with amyotrophic lateral sclerosis: Open-label extension of a phase 2/3 randomized controlled study. (2026/01/15) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Reply to: "Insights and considerations on predicting cognitive and Behavioral disturbances in MND with pure motor onset". (2026/01/15) ♡
- Neuroprotective, eco-friendly iron oxide nanoparticles to alleviate Parkinson's disease symptoms and improve nursing care. (2026/01/12) ♡
- Apolipoprotein A1 reduces blood-spinal cord barrier leakage, improves astrocytic coverage, and enhances motor neuron survival to restore the neurovascular unit in ALS mice. (2026/01/12) ♡
- Exploring rare coding variants in UK biobank: preliminary associations with motor neuron disease. (2026/01/09) ♡
- Development and validation of predictive models for 6-month gastrostomy timing in amyotrophic lateral sclerosis. (2026/01/09) ♡
- ATH-1105 mitigates multiple pathologies in ALS models both alone and in combination with riluzole. (2026/01/08) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Swallowing and feeding after disease-modifying treatment for spinal muscular atrophy: a systematic review of assessment modalities and outcomes. (2026/01/08) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Alterations in intramuscular connective tissue in hypertonic muscle: a scoping review. (2026/01/07) ♡
- Shared mechanisms and pathological phenotypes underlying aminoacyl-tRNA synthetase-related neuropathies. (2026/01/01) ♡
- Protrudin acts at ER-endosome contacts to promote KIF5-mediated endosomal tubule fission. (2026/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The rise and deceleration of neuronal excitability in aging and Alzheimer's disease: Mechanisms, implications, and therapeutic targets. (2026/01/01) ♡
- Axonal Eif5a hypusination controls local translation and mitigates defects in FUS-ALS. (2026/01/01) ♡
- Reduced cortico-muscular output is associated with intrinsic hypoexcitability and reduced persistent inward currents in motor cortex neurons of TDP-43(Q331K) ALS mice. (2026/01/01) ♡
- Nuclear ASC speck formation in microglia is associated with inflammasome priming and is exacerbated in LRRK2-G2019S Parkinson's disease. (2026/01/01) ♡
- Ulva polysaccharide alleviates Parkinson's disease by regulating inflammation, oxidative damage, and gut microbiota. (2026/01/01) ♡
- Case Report of Andersen-Tawil Syndrome: Rare Presentation of a Rare Disease. (2026/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Pathological microtubule dynamics in Parkinson's disease: Mechanisms and therapeutic implications. (2026/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Bioanalytical approaches applied to identify cytoskeletal proteins associated with neurodegenerative diseases. (2026/01/01) ♡
- Global, Regional, and National Epidemiological Burden of Motor Neuron Disease: A Comprehensive Assessment of Prevalence, Incidence, Mortality, and Disability-Adjusted Life Years with Projections to 2036. (2026/01/01) ♡
- A traditional Chinese formula-Lingjiao Gouteng decoction protects dopaminergic neurons from Parkinson's disease via systematic modulation of phospholipid redox metabolism. (2026/01/01) ♡
- Multidimensional predictors of fatigue in amyotrophic lateral sclerosis: a cross-sectional study in China. (2026/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Mitochondrial dysfunction and oxidative stress in Parkinson's disease: mechanisms, biomarkers, and therapeutic strategies. (2026/01/01) ♡
- Role of LXRβ in oligodendrocytes in neuronal survival. (2026/01/01) ♡
- Computational Pipelines for Protein Ubiquitylation Analysis and Prediction. (2026/01/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Molecular insights of peroxisome proliferator-activated receptor-γ signalling in amyotrophic lateral sclerosis and Huntington's disease. (2026/01/01) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis (2026-08-11) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) (2026-08-11) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (2026-08-11) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study (2026-08-10) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study (2026-08-10) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Therapeutic Approach of Repeated Transient Blood-brain Barrier Opening in Amyotrophic Lateral Sclerosis. (2026-08-10) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia (2026-08-07) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.